Protein-Based COVID-19 Vaccines Gain Ground With Novavax’s Targeted FDA Approval

Novavax's traditional vaccine offers a proven alternative amid shifting booster policies and emerging variants

Topline

Novavax's protein-based COVID-19 vaccine, NVX-CoV2373 (Nuvaxovid), has received full FDA approval but only for adults 65 and older and individuals 12 to 64 with underlying risk factors. Backed by strong efficacy data from U.S. and international trials, this vaccine represents a reliable, non-mRNA option as the future of COVID-19 booster policy co…